Convatec announced today that it received FDA approval for the delivery of a Parkinson’s disease therapy through its Neria Guard infusion set.
The FDA approved apomorphine hydrochloride for subcutaneous infusion for the treatment of Parkinson’s. London-based Convatec’s Neria Guard set delivers the therapy under the skin (subcutaneous) as a continuous infusion via a small portable infusion pump. It eliminates the need for an invasive surgical procedure.
Convatec designed Neria Guard insertion technology for ease and simplicity. Its one touch button protects against human error and improves patient independence.
“Patients already know how user-friendly our Neria Guard is and now with this new U.S. FDA approval, we’re able to expand its use to include apomorphine treatment in U.S., following its success in Europe,” said Kjersti Grimsrud, president & COO, Infusion Care at Convatec said. “Having new treatment options is a big win for Parkinson’s patients and their families, and we are very pleased that we can help give more independence to people to live their daily lives.”
Convatec launched its Neria Guard infusion set in 2017. The company cites wide use for the technology in delivering Parkinson’s disease therapies in Europe. It plans to expand the use of its infusion technology with apomorphine through its partners to include U.S. patients.
